MMV and partners manage a portfolio of 65 projects, the largest portfolio of antimalarial R&D and access projects ever assembled.
The portfolio includes nine new drugs in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda.
Go to MMV's portfolio to learn more about the following:
- Cipargamin (KAE609)
- Dihydro-artemisinin-piperaquine Paediatric